Eyecare

This systematic review and meta-analysis looked the impact of myopia (nearsightedness) and strabismus (misalignment of the eyes) on children.

Researchers in Switzlerland reported results from a small, proof-of-concept study in JAMA Ophthalmology that suggest an iPhone 11 and an app may be superior to traditional measurement with an Hertel exophthalmometer.

MSU researchers are hopeful that this new insight about cholesterol crystals in the retina could provide an opportunity for earlier diagnosis and treatment of diabetic retinopathy.

Miebo, approved in May, addresses tear evaporation in dry eye disease. It will have a wholesale acquisition cost of $771 for a one-month supply.

Researchers at Mass Eye and Ear and Dana-Farber Cancer Institute have developed a new technique for growing stem cells harvested from the eye that meets the FDA’s regulatory requirements for tissue engineering.

The anti-cancer drug bevacizumab is used off-label to treat wet AMD. Outlook Therapeutics had developed an ophthalmic formulation of bevacizumab for intravitreal injection.

The anti-cancer drug bevacizumab is used off-label to treat wet AMD. Outlook Therapeutics had developed an ophthalmic formulation of bevacizumab for intravitreal injection.

The higher dose of Eylea allows longer intervals between injections for patients with macular degeneration and diabetic retinopathy. It will have a list price of $2,625 per single-use vial.

The patient was in her 70s and began experiencing the floaters the day after undergoing treatment.

Less than 3% of cataract surgery patients received the sustained-released corticosteroids. The authors argue that the price of more than $500 is an unintentional consequence of rules that require relatively high prices to meet the thresholds for the cost of the news drugs to be passed through to the Medicare program.

Izervay, which is expected to be available within the two to four weeks, will have a list price of $2,100 per vial.

Izervay, which is administered with an intravitreal injection, is expected to be available within the two to four weeks.

The researchers estimate that optimizing vision could prevent up to 100,000 prevalent cases of dementia. They call for clinical trials to test the proposition that optimizing vision would have a preventive effect on dementia.

ABBV-RGX-314 delivers a gene encoding a therapeutic antibody fragment to inhibit vascular endothelial growth factor (VEGF). Early results show it is well-tolerated and leads to improved disease.

Patients with geographic atrophy and their caregivers would benefit from support and accommodations related to managing daily life activities and social activities, as well as their mental health, Sophie J. Bakri, M.D., said during her presentation

Xdemvy is the first treatment that directly targets the mites involved in Demodex blepharitis. It is expected to be available by the end of August 2023 and will have a list price of $1,850 per prescription.

Findings reported in JAMA Ophthalmology chip away at one of the reasons for expanding optometrist scope of practice to include office-based laser procedures. But travel time is not the whole story.

Medical specialties are beginning to look at the environmental impacts of their areas of medicine. A review published in Ophthalmology homed in on cataract surgery and steps that might be taken to reduce greenhouse gas emissions associated with one of the most commonly performed surgeries.

Idiopathic multifocal choroiditis is a rare condition that typically occurs in young women with myopia. A genome-wide association study conducted by Dutch researchers identified a genetic variant that is associated with the disease and implicates dysregulation of the complement system as a possible cause.

At issue is an ongoing review of inspection results from a third-party filling company. No issues were cited in the FDA’s complete response letter about clinical efficacy or safety.

Overall, Descemet membrane endothelial keratoplasty cost less than Descemet stripping automated endothelial keratoplasty and can be done faster, according to findings reported by University of Michigan researchers.

Results reported in JAMA Ophthalmology show that about 20% of those with diabetic retinopathy have a case that could threaten their vision.

The Dry Eye Foundation reported 205 eye drops to the FDA that were not found in the FDA database.

Regulators indicated there was a lack of evidence of effectiveness and lack of clinical trials done to support the application.

The FDA has approved two novel therapies for patients with dry eye disease: Vevye (previously CyclASol) is a water-free, preservative-free solution, and Miebo, which address the excessive tear evaporation that is seen with dry eye.

Vevye (previously CyclASol) is a water-free, preservative-free solution, which allows for improved bioavailability and better efficacy on the target tissue.

Exposure to second-hand smoke may be more harmful for young children than adults because of their faster respiratory rate.

Researchers using data from prospective cohort studies identify higher levels of diglycerides and triglycerides in the blood as possibly playing an important role in the multifactorial causation of glaucoma.

Findings reported in JAMA Opthalmology show substantial decrease from 30 years ago.

Study shows the risk after COVID-19 vaccination is comparable to risk after flu and Tdap vaccine, and that the risk from COVID-19 infection is much greater.